Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Belite Bio Submits Tinlarebant Applications in Three Markets for Rare Eye Disease

Belite Bio Submits Tinlarebant Applications in Three Markets for Rare Eye Disease

MT newswireMT newswire2026/10/14 20:33
04:33 PM EDT, 10/14/2026 (MT Newswires) -- Belite Bio (BLTE) has submitted marketing authorization applications in Singapore, the UK and Switzerland for tinlarebant, an investigational treatment for Stargardt disease type 1, it said Wednesday. STGD1 is a rare retinal disease caused due to mutations in the ABCA4 gene that leads to progressive and irreversible loss of vision, according to a statement. The submissions follow accepted new drug applications in the US and Japan, the company said, adding that the US application has a Prescription Drug User Fee Act target action date of Feb. 12, 2027.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases

Jim Cramer called Intel his top stock pick, but its share price is down about 61% from its historical high. Intel lowered its Q4 revenue guidance to below $16.5 billion. CEO Pat Gelsinger recently bought 150,000 additional shares. Meanwhile, a shareholder lawsuit accuses the company of underestimating the weakness in the PC market.

智通财经•2026/11/17 03:51
Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases